The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake

Ikena Oncology is set to acquire a South San Francisco startup after Gilead Sciences waived its exclusive option to buy the company in March. Plus other life sciences news you may have missed.

Report shows Triad office vacancy rate rises in second quarter

Downtown Orlando building with Gringos Locos sells, renovations planned

‘Neglected’ industries get a new backer with The 81 Collection

Clayton developer goes back to drawing board after plans rejected

The number of “rich” renters in metro Denver is surging

$16M mixed-use Lenexa project planned for space next to The Yard

So, you want to spend your summer vacation on Nantucket?

Walmart is subleasing a four-building, 720,000-square-foot Sunnyvale campus from Meta

The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake

Previous Cook Out expansion rolls into Apex

Next Jeff's Donuts opens sixth Louisville-area location in Springhurst

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Dayton-area realtors share tips for a successful real estate career

Hattie B’s Hot Chicken original location to expand in Midtown

Harmony BioSciences’ shares fall following critical short-seller report

‘Place to recreate’: Tucker bets on town green to bolster downtown

And now we reveal the top private schools for 2023 across the D.C. region

Sprouts Farmers Market coming to Miramar Square

MENU

FirstStar Group

More Stories

Toronto-Dominion No Longer a Laggard in Canadian Banking

Previous Cook Out expansion rolls into Apex

Next Jeff's Donuts opens sixth Louisville-area location in Springhurst

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories